Tilray | TRLY - Equity Capital And Reserves


Tilray reported $1.58B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acasti Pharma USD 62.82M 732K Sep/2025
Akebia Therapeutics USD 32.61M 8.98M Dec/2025
Alaunos Therapeutics USD 2.8M 858K Sep/2025
Aurora Cannabis CAD 536.36M 30.74M Dec/2025
Avita Medical AUD -16.65M 3.76M Dec/2025
Canopy Growth CAD 758.17M 22.16M Dec/2025
Cronos Group USD 1.09B 11.39M Dec/2025
Dianthus Therapeutics USD 493.4M 53.05M Dec/2025
Divis Laboratories Ltd INR 154.13B 4.44B Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
IQVIA Holdings USD 6.5B 343M Dec/2025
Knight Therapeutics CAD 767.27M 480K Dec/2025
Moderna USD 8.65B 680M Dec/2025
Organigram Holdings CAD 369.46M 20.33M Dec/2025
Organon & Co USD 906M 173M Sep/2025
Revvity USD 7.38B 180.27M Sep/2025
Tectonic Therapeutic USD 251.33M 16.2M Dec/2025
Tilray USD 1.58B 39.08M Sep/2025
Viatris USD 15.22B 352.9M Sep/2025
Xeris Pharmaceuticals USD 13.69M 14.55M Dec/2025
Zealand Pharma A/S 14.83B 331.99M Dec/2025